Steroid-Induced Hyperglycemia

Refer directly for emergency assessment when blood glucose is greater than 15 mmol/L (270 mg/dL) with ketones greater than 2 mmol/L, indicating high risk for diabetic ketoacidosis, or when glucose is persistently greater than 20 mmol/L (360 mg/dL) or registers as "HI," suggesting hyperosmolar hyperglycemic state risk. BMJBMJHyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations | Journal for ImmunoTherapy of Cancer

For nonemergent patients, document the glucocorticoid agent, dose, route, dosing frequency, and anticipated taper or stop date before selecting insulin. Glucocorticoids increase hepatic glucose production, impair peripheral glucose uptake, and increase insulin resistance; the clinical result is commonly disproportionate postprandial rather than fasting hyperglycemia. Wolters Kluwer+1Wolters KluwerThe Impact of Insulin Degludec on... : Journal of DiabetologyScienceDirectInsulin Dosing and Glycemic Outcomes Among Steroid-treated Hospitalized Patients

Obtain bedside point-of-care glucose monitoring for any inpatient receiving glucocorticoids, including patients without known diabetes. A random glucose above 140 mg/dL identifies inpatient hyperglycemia requiring clinical attention, while repeated values of at least 11.1 mmol/L (200 mg/dL) during steroid exposure support steroid-induced hyperglycemia in a patient without prior diabetes. Oxford Academic+2Oxford AcademicManagement of Hyperglycemia in Hospitalized Patients in Non ...The LancetManagement of diabetes and hyperglycaemia in the hospitalBMJHyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations | Journal for ImmunoTherapy of Cancer

With most glucocorticoid regimens, preferentially assess postprandial glucose because glucocorticoid exposure produces greater postprandial than fasting hyperglycemia. A normal fasting result does not exclude clinically meaningful steroid-induced hyperglycemia, particularly after a single morning dose of an intermediate-acting agent. ScienceDirect+1ScienceDirectInsulin Dosing and Glycemic Outcomes Among Steroid-treated Hospitalized PatientsPubMedGlucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem - PMC

For cyclic or intermittent high-dose steroid regimens, obtain glucose screening before each treatment cycle and again 4 to 6 hours after glucocorticoid intake. This approach detected steroid-associated hyperglycemia in hematologic patients and targets the expected early rise after dosing. Wolters KluwerWolters KluwerGlucocorticoid-induced hyperglycemia in... : The Egyptian Journal of Haematology

Reassess glucose values whenever the glucocorticoid dose, timing, formulation, or frequency changes. Insulin needs follow steroid exposure; a regimen that is adequate during high-dose therapy can cause hypoglycemia after a steroid reduction or discontinuation. BMJBMJHyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations | Journal for ImmunoTherapy of Cancer

Initiate insulin for persistent hyperglycemia while the patient is receiving glucocorticoid therapy. In moderate to severe steroid-induced hyperglycemia, insulin is the principal treatment approach; morning intermediate-acting isophane insulin or morning mixed insulin can be matched to the glycemic effect of steroid treatment. Oxford Academic+1Oxford AcademicAn Endocrine Society Clinical Practice Guideline - Oxford AcademicBMJHyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations | Journal for ImmunoTherapy of Cancer

For a morning intermediate-acting glucocorticoid regimen with predominantly later-day glucose elevation, consider morning NPH/isophane insulin because its action profile can be aligned to the anticipated steroid-related glucose rise. If the patient requires a basal-bolus regimen, either NPH or insulin glargine can serve as basal insulin: a randomized trial in hospitalized adults with type 2 diabetes, respiratory disease, and medium- to high-dose intermediate-acting corticosteroids found the two basal strategies equally effective within a basal-bolus protocol. BMJ+1BMJHyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations | Journal for ImmunoTherapy of CancerScienceDirectRandomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease - ScienceDirect

For long-acting dexamethasone or intermediate-acting methylprednisolone associated with hyperglycemia throughout the day, do not assume a single fasting measurement captures control. Use serial glucose results across the day to judge whether the current basal-bolus exposure covers the sustained pattern. Wolters Kluwer+1Wolters KluwerThe Impact of Insulin Degludec on... : Journal of DiabetologyScienceDirectInsulin Dosing and Glycemic Outcomes Among Steroid-treated Hospitalized Patients

Whenever glucocorticoids are substantially reduced, reassess the diabetes regimen at the same time. Steroids are the principal driver of the added insulin requirement, and failure to lower glucose-lowering therapy as steroid exposure decreases is a frequent cause of hypoglycemia. BMJBMJHyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations | Journal for ImmunoTherapy of Cancer

At discharge or during outpatient steroid adjustment, give the patient a glucose-monitoring plan, hypoglycemia education if insulin or another hypoglycemia-producing therapy is used, and explicit instructions to contact the treating team when steroid dosing changes. Education should include symptoms of severe hyperglycemia and thresholds for hospital presentation. BMJBMJHyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations | Journal for ImmunoTherapy of Cancer

Patients with preexisting diabetes require particular attention because glucocorticoids can worsen existing hyperglycemia, while patients without known diabetes may have unmasked diabetes or transient steroid-related dysglycemia. Continued follow-up should therefore be guided by glucose trajectory after steroid withdrawal and baseline HbA1c when available. PubMed+1PubMedGlucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem - PMCBMJHyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations | Journal for ImmunoTherapy of Cancer